Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.
Stocks · News reference
Benzinga Bulls and Bears: Ross, Moderna, Webull
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead
Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
Georgia Rep. Richard Dean Dr McCormick Bought Up to $15K Worth of Berkshire Hathaway Stock
A October filing shows that Representative Richard Dean Dr McCormick reported a purchase in Berkshire Hathaway (NYSE:BRK), valued between $1,001 and $15,000. The transaction date is listed as September 18, 2026, with
QUICK SPARK: Berkshire Stock Is Doing Something It Hasn’t Done Since January 2018
Berkshire Hathaway has risen 10 sessions in a row, its first such streak since January 2018 and the first under CEO Greg Abel.
Berkshire Hathaway Doubles Down on Bending Spoons with $330 Million Investment, Sending Shares Soaring 45%
Bending Spoons stock surges 45% as Berkshire Hathaway invests another $330 million, raising its stake to 4% and backing future acquisitions.
Shares of banks and financial services companies are trading lower after U.S. core inflation data bolstered the case for more Fed monetary tightening, which may slow lending and limit interest margins. Also, weak Q3 segment results from Bank of America and Morgan Stanley may dent confidence in the broader sector.